SecBot SecBot

FOLD

AMICUS THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001178879 Biotech & Drug Discovery
No price
Median target
$14.50
range $14.50–14.50
Insider net
$0
no open-market trades · since Apr 27
New fund stakes
0
Q2 2026 13F · 46 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 3 reports · latest
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Apr 27. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 46 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.093 → −$0.082 over 90 days. 0 up, 1 down in 30 days.

Who's buying

13F· Q2 2026
0
new positions
46
exits
FundMoveSharesValue
NORGES BANKEXIT0$0.00
STATE STREET CORPEXIT0$0.00
GEODE CAPITAL MANAGEMENT, LLCEXIT0$0.00
JPMORGAN CHASE & COEXIT0$0.00
FMR LLCEXIT0$0.00
MORGAN STANLEYEXIT0$0.00
BANK OF AMERICA CORP /DE/EXIT0$0.00
GOLDMAN SACHS GROUP INCEXIT0$0.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jan 2026
Recent actions
DateFirmActionRating
Jan 22, 2026Jefferies
DOWNGRADE
DOWNGRADEHold
Dec 29, 2025Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform
Dec 22, 2025Citigroup
DOWNGRADE
DOWNGRADENeutral
Dec 19, 2025Needham
DOWNGRADE
DOWNGRADEHold
Dec 19, 2025Cantor Fitzgerald
DOWNGRADE
DOWNGRADENeutral
Dec 17, 2025Citigroup
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · since Apr 27
DateInsiderTypeValue
Apr 27, 2026
Clark David Michael
Chief People Officer
Apr 27, 2026
TO ISSUER83,221 sh
Apr 27, 2026
Rosenberg Ellen
Chief Legal Officer
Apr 27, 2026
TO ISSUER108,980 sh
Apr 27, 2026
Clark David Michael
Chief People Officer
Apr 27, 2026
TO ISSUER108,266 sh
Apr 27, 2026
Clark David Michael
Chief People Officer
Apr 27, 2026
TO ISSUER91,439 sh
Apr 27, 2026
Rosenberg Ellen
Chief Legal Officer
Apr 27, 2026
TO ISSUER203,825 sh
Apr 27, 2026
Harford Simon N.R.
Chief Financial Officer
Apr 27, 2026
TO ISSUER99,073 sh
Apr 27, 2026
Harford Simon N.R.
Chief Financial Officer
Apr 27, 2026
TO ISSUER150,517 sh
Apr 27, 2026
Campbell Bradley L
President and CEO
Apr 27, 2026
TO ISSUER$14.6M

Earnings setup

Estimates
−$0.08
EPS estimate, this quarter
−188%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current FY$0.07$0.07–$0.07-88.8%$752.4M
Next FY$0.82$0.47–$0.97-10.8%$888.5M
Next Q$0.02$0.02–$0.02-89.6%$180.9M
Current Q-$0.08-$0.08–-$0.08-188.0%$159.6M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 25, 2026 Clinical trial readout
T-90d Trial Readout: migalastat HCl 150 mg (Phase 3)
Trial: A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Aug 12, 2026 Event
POMBILITI ATGA
WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIOR
Jun 30, 2026 Inst.
NORGES BANK · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
STATE STREET CORP · EXIT
0 shares ($0.00)
May 7, 2026 SEC
Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin…
15-12G · Impact 4/10
Apr 27, 2026 SEC
Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting…
8-K · Impact 9/10
Apr 27, 2026 Insider
Clark David Michael disposed of 83,221 shares
Chief People Officer
Apr 27, 2026 Insider
Rosenberg Ellen disposed of 108,980 shares
Chief Legal Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

Washington

Corporate Lobbying

9 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All FOLD filing & press-release reports (3)